MSP Recovery, Inc.
Get $10 bonus on your first $100 deposit for MSPR
Get $10 bonus on your first $100 deposit for MSPR
MSP Recovery, Inc. (MSPR) Stock Competitors & Peer Comparison
See (MSPR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MSPR | $0.03 | +6.53% | 427K | N/A | -$2,345.39 | N/A |
| GEHC | $70.35 | -2.26% | 32.1B | 15.46 | $4.55 | +0.20% |
| VEEV | $174.07 | +0.77% | 28.6B | 32.00 | $5.44 | N/A |
| BTSGU | $143.86 | -0.57% | 27.8B | N/A | N/A | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| BTSG | $43.10 | +2.55% | 8.3B | 89.79 | $0.48 | N/A |
| TEM | $47.39 | +0.77% | 8.2B | -33.61 | -$1.41 | N/A |
| HQY | $84.67 | +1.55% | 7.2B | 34.42 | $2.46 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
MSPR vs GEHC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, GEHC has a market cap of 32.1B. Regarding current trading prices, MSPR is priced at $0.03, while GEHC trades at $70.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 15.46. In terms of profitability, MSPR's ROE is +3.93%, compared to GEHC's ROE of +0.17%. Regarding short-term risk, MSPR is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check GEHC's competition here
MSPR vs VEEV Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, VEEV has a market cap of 28.6B. Regarding current trading prices, MSPR is priced at $0.03, while VEEV trades at $174.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas VEEV's P/E ratio is 32.00. In terms of profitability, MSPR's ROE is +3.93%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, MSPR is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check VEEV's competition here
MSPR vs BTSGU Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BTSGU has a market cap of 27.8B. Regarding current trading prices, MSPR is priced at $0.03, while BTSGU trades at $143.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BTSGU's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to BTSGU's ROE of +0.11%. Regarding short-term risk, MSPR is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check BTSGU's competition here
MSPR vs GEHCV Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, MSPR is priced at $0.03, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas GEHCV's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to GEHCV's ROE of +0.21%. Regarding short-term risk, MSPR is more volatile compared to GEHCV. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check GEHCV's competition here
MSPR vs SGFY Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, MSPR is priced at $0.03, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SGFY's P/E ratio is 70.91. In terms of profitability, MSPR's ROE is +3.93%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, MSPR is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SGFY's competition here
MSPR vs BTSG Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BTSG has a market cap of 8.3B. Regarding current trading prices, MSPR is priced at $0.03, while BTSG trades at $43.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BTSG's P/E ratio is 89.79. In terms of profitability, MSPR's ROE is +3.93%, compared to BTSG's ROE of +0.11%. Regarding short-term risk, MSPR is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check BTSG's competition here
MSPR vs TEM Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, TEM has a market cap of 8.2B. Regarding current trading prices, MSPR is priced at $0.03, while TEM trades at $47.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas TEM's P/E ratio is -33.61. In terms of profitability, MSPR's ROE is +3.93%, compared to TEM's ROE of -0.60%. Regarding short-term risk, MSPR is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check TEM's competition here
MSPR vs HQY Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HQY has a market cap of 7.2B. Regarding current trading prices, MSPR is priced at $0.03, while HQY trades at $84.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HQY's P/E ratio is 34.42. In terms of profitability, MSPR's ROE is +3.93%, compared to HQY's ROE of +0.10%. Regarding short-term risk, MSPR is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check HQY's competition here
MSPR vs RCM Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, RCM has a market cap of 6B. Regarding current trading prices, MSPR is priced at $0.03, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas RCM's P/E ratio is -102.21. In terms of profitability, MSPR's ROE is +3.93%, compared to RCM's ROE of +0.00%. Regarding short-term risk, MSPR is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check RCM's competition here
MSPR vs DOCS Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, DOCS has a market cap of 4.3B. Regarding current trading prices, MSPR is priced at $0.03, while DOCS trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas DOCS's P/E ratio is 19.13. In terms of profitability, MSPR's ROE is +3.93%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, MSPR is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check DOCS's competition here
MSPR vs ONEM Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, MSPR is priced at $0.03, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ONEM's P/E ratio is -7.77. In terms of profitability, MSPR's ROE is +3.93%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, MSPR is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check ONEM's competition here
MSPR vs HNGE Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HNGE has a market cap of 3.1B. Regarding current trading prices, MSPR is priced at $0.03, while HNGE trades at $38.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HNGE's P/E ratio is -5.02. In terms of profitability, MSPR's ROE is +3.93%, compared to HNGE's ROE of -1.32%. Regarding short-term risk, MSPR is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check HNGE's competition here
MSPR vs TXG Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, TXG has a market cap of 2.9B. Regarding current trading prices, MSPR is priced at $0.03, while TXG trades at $22.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas TXG's P/E ratio is -63.80. In terms of profitability, MSPR's ROE is +3.93%, compared to TXG's ROE of -0.06%. Regarding short-term risk, MSPR is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check TXG's competition here
MSPR vs PRVA Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, MSPR is priced at $0.03, while PRVA trades at $21.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PRVA's P/E ratio is 117.83. In terms of profitability, MSPR's ROE is +3.93%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, MSPR is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check PRVA's competition here
MSPR vs PINC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, MSPR is priced at $0.03, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PINC's P/E ratio is 166.24. In terms of profitability, MSPR's ROE is +3.93%, compared to PINC's ROE of -0.02%. Regarding short-term risk, MSPR is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check PINC's competition here
MSPR vs HTFL Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HTFL has a market cap of 2.1B. Regarding current trading prices, MSPR is priced at $0.03, while HTFL trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HTFL's P/E ratio is -7.83. In terms of profitability, MSPR's ROE is +3.93%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, MSPR is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check HTFL's competition here
MSPR vs WGS Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, MSPR is priced at $0.03, while WGS trades at $66.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas WGS's P/E ratio is -90.68. In terms of profitability, MSPR's ROE is +3.93%, compared to WGS's ROE of -0.07%. Regarding short-term risk, MSPR is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check WGS's competition here
MSPR vs NXGN Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, MSPR is priced at $0.03, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas NXGN's P/E ratio is -266.00. In terms of profitability, MSPR's ROE is +3.93%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, MSPR is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check NXGN's competition here
MSPR vs OMCL Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, OMCL has a market cap of 1.6B. Regarding current trading prices, MSPR is priced at $0.03, while OMCL trades at $34.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas OMCL's P/E ratio is 853.75. In terms of profitability, MSPR's ROE is +3.93%, compared to OMCL's ROE of +0.00%. Regarding short-term risk, MSPR is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check OMCL's competition here
MSPR vs AGTI Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, MSPR is priced at $0.03, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas AGTI's P/E ratio is -71.79. In terms of profitability, MSPR's ROE is +3.93%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, MSPR is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check AGTI's competition here
MSPR vs PGNY Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PGNY has a market cap of 1.4B. Regarding current trading prices, MSPR is priced at $0.03, while PGNY trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PGNY's P/E ratio is 25.54. In terms of profitability, MSPR's ROE is +3.93%, compared to PGNY's ROE of +0.11%. Regarding short-term risk, MSPR is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check PGNY's competition here
MSPR vs TDOC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, TDOC has a market cap of 940.1M. Regarding current trading prices, MSPR is priced at $0.03, while TDOC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas TDOC's P/E ratio is -0.15. In terms of profitability, MSPR's ROE is +3.93%, compared to TDOC's ROE of -0.14%. Regarding short-term risk, MSPR is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check TDOC's competition here
MSPR vs CERT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CERT has a market cap of 861.7M. Regarding current trading prices, MSPR is priced at $0.03, while CERT trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CERT's P/E ratio is -541.00. In terms of profitability, MSPR's ROE is +3.93%, compared to CERT's ROE of -0.00%. Regarding short-term risk, MSPR is more volatile compared to CERT. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CERT's competition here
MSPR vs SDGR Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SDGR has a market cap of 854.9M. Regarding current trading prices, MSPR is priced at $0.03, while SDGR trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SDGR's P/E ratio is -8.21. In terms of profitability, MSPR's ROE is +3.93%, compared to SDGR's ROE of -0.29%. Regarding short-term risk, MSPR is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SDGR's competition here
MSPR vs CCLDO Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CCLDO has a market cap of 804.5M. Regarding current trading prices, MSPR is priced at $0.03, while CCLDO trades at $25.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CCLDO's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to CCLDO's ROE of +0.19%. Regarding short-term risk, MSPR is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CCLDO's competition here
MSPR vs OMDA Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, OMDA has a market cap of 741.3M. Regarding current trading prices, MSPR is priced at $0.03, while OMDA trades at $12.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas OMDA's P/E ratio is -35.94. In terms of profitability, MSPR's ROE is +3.93%, compared to OMDA's ROE of -0.07%. Regarding short-term risk, MSPR is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check OMDA's competition here
MSPR vs GDRX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, GDRX has a market cap of 702.5M. Regarding current trading prices, MSPR is priced at $0.03, while GDRX trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas GDRX's P/E ratio is 22.78. In terms of profitability, MSPR's ROE is +3.93%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, MSPR is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check GDRX's competition here
MSPR vs MPLN-WT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, MSPR is priced at $0.03, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to MPLN-WT's ROE of +3.78%. Regarding short-term risk, MSPR is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check MPLN-WT's competition here
MSPR vs HSTM Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HSTM has a market cap of 606.7M. Regarding current trading prices, MSPR is priced at $0.03, while HSTM trades at $20.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HSTM's P/E ratio is 33.52. In terms of profitability, MSPR's ROE is +3.93%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, MSPR is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check HSTM's competition here
MSPR vs NUTX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, NUTX has a market cap of 600.9M. Regarding current trading prices, MSPR is priced at $0.03, while NUTX trades at $100.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas NUTX's P/E ratio is 9.63. In terms of profitability, MSPR's ROE is +3.93%, compared to NUTX's ROE of +0.24%. Regarding short-term risk, MSPR is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check NUTX's competition here
MSPR vs ACCD Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, MSPR is priced at $0.03, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ACCD's P/E ratio is -3.08. In terms of profitability, MSPR's ROE is +3.93%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, MSPR is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check ACCD's competition here
MSPR vs SHCR Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, MSPR is priced at $0.03, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SHCR's P/E ratio is -3.76. In terms of profitability, MSPR's ROE is +3.93%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, MSPR is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SHCR's competition here
MSPR vs PHR Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PHR has a market cap of 504.6M. Regarding current trading prices, MSPR is priced at $0.03, while PHR trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PHR's P/E ratio is 209.25. In terms of profitability, MSPR's ROE is +3.93%, compared to PHR's ROE of -0.07%. Regarding short-term risk, MSPR is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check PHR's competition here
MSPR vs SLGC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, MSPR is priced at $0.03, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SLGC's P/E ratio is -3.04. In terms of profitability, MSPR's ROE is +3.93%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, MSPR is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check SLGC's competition here
MSPR vs SLGCW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, MSPR is priced at $0.03, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, MSPR's ROE is +3.93%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, MSPR is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check SLGCW's competition here
MSPR vs NRC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, NRC has a market cap of 390.3M. Regarding current trading prices, MSPR is priced at $0.03, while NRC trades at $17.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas NRC's P/E ratio is 34.32. In terms of profitability, MSPR's ROE is +3.93%, compared to NRC's ROE of +0.59%. Regarding short-term risk, MSPR is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check NRC's competition here
MSPR vs SY Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SY has a market cap of 377.7M. Regarding current trading prices, MSPR is priced at $0.03, while SY trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SY's P/E ratio is -8.20. In terms of profitability, MSPR's ROE is +3.93%, compared to SY's ROE of -0.14%. Regarding short-term risk, MSPR is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SY's competition here
MSPR vs MPLN Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, MSPR is priced at $0.03, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas MPLN's P/E ratio is -0.23. In terms of profitability, MSPR's ROE is +3.93%, compared to MPLN's ROE of +3.78%. Regarding short-term risk, MSPR is more volatile compared to MPLN. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check MPLN's competition here
MSPR vs SOPH Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SOPH has a market cap of 361.2M. Regarding current trading prices, MSPR is priced at $0.03, while SOPH trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SOPH's P/E ratio is -4.31. In terms of profitability, MSPR's ROE is +3.93%, compared to SOPH's ROE of -1.17%. Regarding short-term risk, MSPR is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SOPH's competition here
MSPR vs CTEV Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CTEV has a market cap of 289M. Regarding current trading prices, MSPR is priced at $0.03, while CTEV trades at $17.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CTEV's P/E ratio is -1.01. In terms of profitability, MSPR's ROE is +3.93%, compared to CTEV's ROE of +3.78%. Regarding short-term risk, MSPR is more volatile compared to CTEV. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CTEV's competition here
MSPR vs TRHC Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, MSPR is priced at $0.03, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas TRHC's P/E ratio is -4.27. In terms of profitability, MSPR's ROE is +3.93%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, MSPR is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check TRHC's competition here
MSPR vs CARL Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CARL has a market cap of 260.1M. Regarding current trading prices, MSPR is priced at $0.03, while CARL trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CARL's P/E ratio is -4.59. In terms of profitability, MSPR's ROE is +3.93%, compared to CARL's ROE of -2.64%. Regarding short-term risk, MSPR is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CARL's competition here
MSPR vs EVH Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, EVH has a market cap of 251.2M. Regarding current trading prices, MSPR is priced at $0.03, while EVH trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas EVH's P/E ratio is -0.44. In terms of profitability, MSPR's ROE is +3.93%, compared to EVH's ROE of -0.69%. Regarding short-term risk, MSPR is more volatile compared to EVH. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check EVH's competition here
MSPR vs SMFR Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, MSPR is priced at $0.03, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SMFR's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to SMFR's ROE of -0.07%. Regarding short-term risk, MSPR is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check SMFR's competition here
MSPR vs TBRG Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, TBRG has a market cap of 243.7M. Regarding current trading prices, MSPR is priced at $0.03, while TBRG trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas TBRG's P/E ratio is 56.00. In terms of profitability, MSPR's ROE is +3.93%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, MSPR is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check TBRG's competition here
MSPR vs SLP Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SLP has a market cap of 241.6M. Regarding current trading prices, MSPR is priced at $0.03, while SLP trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SLP's P/E ratio is -3.75. In terms of profitability, MSPR's ROE is +3.93%, compared to SLP's ROE of -0.45%. Regarding short-term risk, MSPR is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SLP's competition here
MSPR vs SPOK Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SPOK has a market cap of 230.7M. Regarding current trading prices, MSPR is priced at $0.03, while SPOK trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SPOK's P/E ratio is 14.84. In terms of profitability, MSPR's ROE is +3.93%, compared to SPOK's ROE of +0.11%. Regarding short-term risk, MSPR is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SPOK's competition here
MSPR vs CCLD Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CCLD has a market cap of 142.4M. Regarding current trading prices, MSPR is priced at $0.03, while CCLD trades at $3.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CCLD's P/E ratio is 33.50. In terms of profitability, MSPR's ROE is +3.93%, compared to CCLD's ROE of +0.19%. Regarding short-term risk, MSPR is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CCLD's competition here
MSPR vs CPSI Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, MSPR is priced at $0.03, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CPSI's P/E ratio is -183.80. In terms of profitability, MSPR's ROE is +3.93%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, MSPR is more volatile compared to CPSI. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CPSI's competition here
MSPR vs OPRX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, OPRX has a market cap of 123.1M. Regarding current trading prices, MSPR is priced at $0.03, while OPRX trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas OPRX's P/E ratio is 24.30. In terms of profitability, MSPR's ROE is +3.93%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, MSPR is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check OPRX's competition here
MSPR vs AUGX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, MSPR is priced at $0.03, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas AUGX's P/E ratio is -4.99. In terms of profitability, MSPR's ROE is +3.93%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, MSPR is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check AUGX's competition here
MSPR vs DH Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, DH has a market cap of 112.8M. Regarding current trading prices, MSPR is priced at $0.03, while DH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas DH's P/E ratio is -0.83. In terms of profitability, MSPR's ROE is +3.93%, compared to DH's ROE of -0.47%. Regarding short-term risk, MSPR is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check DH's competition here
MSPR vs AMWL Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, AMWL has a market cap of 91M. Regarding current trading prices, MSPR is priced at $0.03, while AMWL trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas AMWL's P/E ratio is -0.92. In terms of profitability, MSPR's ROE is +3.93%, compared to AMWL's ROE of -0.36%. Regarding short-term risk, MSPR is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check AMWL's competition here
MSPR vs HCAT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HCAT has a market cap of 86.1M. Regarding current trading prices, MSPR is priced at $0.03, while HCAT trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HCAT's P/E ratio is -0.46. In terms of profitability, MSPR's ROE is +3.93%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, MSPR is more volatile compared to HCAT. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check HCAT's competition here
MSPR vs FORA Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, FORA has a market cap of 65.3M. Regarding current trading prices, MSPR is priced at $0.03, while FORA trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas FORA's P/E ratio is -23.33. In terms of profitability, MSPR's ROE is +3.93%, compared to FORA's ROE of -0.09%. Regarding short-term risk, MSPR is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check FORA's competition here
MSPR vs CCLDP Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, MSPR is priced at $0.03, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CCLDP's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to CCLDP's ROE of +0.19%. Regarding short-term risk, MSPR is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CCLDP's competition here
MSPR vs BEAT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BEAT has a market cap of 40.6M. Regarding current trading prices, MSPR is priced at $0.03, while BEAT trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BEAT's P/E ratio is -1.90. In terms of profitability, MSPR's ROE is +3.93%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, MSPR is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check BEAT's competition here
MSPR vs SNCE Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, MSPR is priced at $0.03, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SNCE's P/E ratio is -0.27. In terms of profitability, MSPR's ROE is +3.93%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, MSPR is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SNCE's competition here
MSPR vs AKLI Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, MSPR is priced at $0.03, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas AKLI's P/E ratio is -0.71. In terms of profitability, MSPR's ROE is +3.93%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, MSPR is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check AKLI's competition here
MSPR vs SHLT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, MSPR is priced at $0.03, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SHLT's P/E ratio is -3.87. In terms of profitability, MSPR's ROE is +3.93%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, MSPR is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SHLT's competition here
MSPR vs SHCRW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, MSPR is priced at $0.03, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, MSPR's ROE is +3.93%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, MSPR is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check SHCRW's competition here
MSPR vs ONMD Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ONMD has a market cap of 30.5M. Regarding current trading prices, MSPR is priced at $0.03, while ONMD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ONMD's P/E ratio is -15.50. In terms of profitability, MSPR's ROE is +3.93%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, MSPR is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check ONMD's competition here
MSPR vs STRM Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, MSPR is priced at $0.03, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas STRM's P/E ratio is -2.40. In terms of profitability, MSPR's ROE is +3.93%, compared to STRM's ROE of -0.50%. Regarding short-term risk, MSPR is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check STRM's competition here
MSPR vs RNLX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, MSPR is priced at $0.03, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas RNLX's P/E ratio is -0.33. In terms of profitability, MSPR's ROE is +3.93%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, MSPR is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check RNLX's competition here
MSPR vs LIFW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, MSPR is priced at $0.03, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas LIFW's P/E ratio is -0.02. In terms of profitability, MSPR's ROE is +3.93%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, MSPR is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check LIFW's competition here
MSPR vs EUDA Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, EUDA has a market cap of 17.8M. Regarding current trading prices, MSPR is priced at $0.03, while EUDA trades at $9.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas EUDA's P/E ratio is 23.50. In terms of profitability, MSPR's ROE is +3.93%, compared to EUDA's ROE of +0.14%. Regarding short-term risk, MSPR is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check EUDA's competition here
MSPR vs BBLN Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, MSPR is priced at $0.03, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BBLN's P/E ratio is -0.04. In terms of profitability, MSPR's ROE is +3.93%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, MSPR is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check BBLN's competition here
MSPR vs BFRG Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BFRG has a market cap of 12.7M. Regarding current trading prices, MSPR is priced at $0.03, while BFRG trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BFRG's P/E ratio is -1.90. In terms of profitability, MSPR's ROE is +3.93%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, MSPR is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check BFRG's competition here
MSPR vs ETAO Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, MSPR is priced at $0.03, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ETAO's P/E ratio is -0.01. In terms of profitability, MSPR's ROE is +3.93%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, MSPR is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check ETAO's competition here
MSPR vs HLTH Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, MSPR is priced at $0.03, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HLTH's P/E ratio is -0.02. In terms of profitability, MSPR's ROE is +3.93%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, MSPR is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check HLTH's competition here
MSPR vs ZCMD Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ZCMD has a market cap of 5.7M. Regarding current trading prices, MSPR is priced at $0.03, while ZCMD trades at $1.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ZCMD's P/E ratio is -1.16. In terms of profitability, MSPR's ROE is +3.93%, compared to ZCMD's ROE of -0.08%. Regarding short-term risk, MSPR is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check ZCMD's competition here
MSPR vs UPH Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, MSPR is priced at $0.03, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas UPH's P/E ratio is -0.07. In terms of profitability, MSPR's ROE is +3.93%, compared to UPH's ROE of -1.05%. Regarding short-term risk, MSPR is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check UPH's competition here
MSPR vs UPH-WT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, MSPR is priced at $0.03, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, MSPR is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check UPH-WT's competition here
MSPR vs SCNX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, SCNX has a market cap of 4.6M. Regarding current trading prices, MSPR is priced at $0.03, while SCNX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.11. In terms of profitability, MSPR's ROE is +3.93%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, MSPR is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check SCNX's competition here
MSPR vs BEATW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BEATW has a market cap of 4.1M. Regarding current trading prices, MSPR is priced at $0.03, while BEATW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BEATW's P/E ratio is -0.24. In terms of profitability, MSPR's ROE is +3.93%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, MSPR is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check BEATW's competition here
MSPR vs PEARW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, MSPR is priced at $0.03, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PEARW's P/E ratio is -0.00. In terms of profitability, MSPR's ROE is +3.93%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, MSPR is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check PEARW's competition here
MSPR vs PEAR Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, MSPR is priced at $0.03, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas PEAR's P/E ratio is -0.08. In terms of profitability, MSPR's ROE is +3.93%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, MSPR is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check PEAR's competition here
MSPR vs VSEE Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, VSEE has a market cap of 3.6M. Regarding current trading prices, MSPR is priced at $0.03, while VSEE trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas VSEE's P/E ratio is 0.48. In terms of profitability, MSPR's ROE is +3.93%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, MSPR is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check VSEE's competition here
MSPR vs MGRX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, MGRX has a market cap of 3.4M. Regarding current trading prices, MSPR is priced at $0.03, while MGRX trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas MGRX's P/E ratio is -0.16. In terms of profitability, MSPR's ROE is +3.93%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, MSPR is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check MGRX's competition here
MSPR vs BFRGW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, BFRGW has a market cap of 3.1M. Regarding current trading prices, MSPR is priced at $0.03, while BFRGW trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas BFRGW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, MSPR is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check BFRGW's competition here
MSPR vs HCTI Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, HCTI has a market cap of 2.9M. Regarding current trading prices, MSPR is priced at $0.03, while HCTI trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas HCTI's P/E ratio is -0.03. In terms of profitability, MSPR's ROE is +3.93%, compared to HCTI's ROE of -1.13%. Regarding short-term risk, MSPR is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check HCTI's competition here
MSPR vs OTRK Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, MSPR is priced at $0.03, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas OTRK's P/E ratio is -0.02. In terms of profitability, MSPR's ROE is +3.93%, compared to OTRK's ROE of -2.04%. Regarding short-term risk, MSPR is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check OTRK's competition here
MSPR vs ACON Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ACON has a market cap of 1.9M. Regarding current trading prices, MSPR is priced at $0.03, while ACON trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ACON's P/E ratio is -0.26. In terms of profitability, MSPR's ROE is +3.93%, compared to ACON's ROE of -0.00%. Regarding short-term risk, MSPR is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check ACON's competition here
MSPR vs CMAX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, MSPR is priced at $0.03, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CMAX's P/E ratio is -0.00. In terms of profitability, MSPR's ROE is +3.93%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, MSPR is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CMAX's competition here
MSPR vs LIFWZ Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, MSPR is priced at $0.03, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, MSPR is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check LIFWZ's competition here
MSPR vs VSEEW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, VSEEW has a market cap of 1.2M. Regarding current trading prices, MSPR is priced at $0.03, while VSEEW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas VSEEW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, MSPR is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check VSEEW's competition here
MSPR vs EUDAW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, EUDAW has a market cap of 775.1K. Regarding current trading prices, MSPR is priced at $0.03, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas EUDAW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to EUDAW's ROE of +0.14%. Regarding short-term risk, MSPR is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check EUDAW's competition here
MSPR vs MSPRZ Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, MSPR is priced at $0.03, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, MSPR is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check MSPRZ's competition here
MSPR vs WORX Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, WORX has a market cap of 490.1K. Regarding current trading prices, MSPR is priced at $0.03, while WORX trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas WORX's P/E ratio is -0.14. In terms of profitability, MSPR's ROE is +3.93%, compared to WORX's ROE of -0.73%. Regarding short-term risk, MSPR is more volatile compared to WORX. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check WORX's competition here
MSPR vs WGSWW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, WGSWW has a market cap of 226.3K. Regarding current trading prices, MSPR is priced at $0.03, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas WGSWW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to WGSWW's ROE of -0.07%. Regarding short-term risk, MSPR is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check WGSWW's competition here
MSPR vs KERN Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, MSPR is priced at $0.03, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas KERN's P/E ratio is -0.01. In terms of profitability, MSPR's ROE is +3.93%, compared to KERN's ROE of -0.02%. Regarding short-term risk, MSPR is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check KERN's competition here
MSPR vs KERNW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, MSPR is priced at $0.03, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas KERNW's P/E ratio is -0.00. In terms of profitability, MSPR's ROE is +3.93%, compared to KERNW's ROE of -0.02%. Regarding short-term risk, MSPR is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check KERNW's competition here
MSPR vs LIFWW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, MSPR is priced at $0.03, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas LIFWW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, MSPR is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check LIFWW's competition here
MSPR vs OTRKP Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, MSPR is priced at $0.03, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, MSPR's ROE is +3.93%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, MSPR is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check OTRKP's competition here
MSPR vs CMAXW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, MSPR is priced at $0.03, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas CMAXW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, MSPR is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check CMAXW's competition here
MSPR vs ACONW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ACONW has a market cap of 17.7K. Regarding current trading prices, MSPR is priced at $0.03, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ACONW's P/E ratio is -0.01. In terms of profitability, MSPR's ROE is +3.93%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, MSPR is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check ACONW's competition here
MSPR vs ICCT Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, ICCT has a market cap of 9.8K. Regarding current trading prices, MSPR is priced at $0.03, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas ICCT's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, MSPR is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check ICCT's competition here
MSPR vs FOXO Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, MSPR is priced at $0.03, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas FOXO's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to FOXO's ROE of -0.80%. Regarding short-term risk, MSPR is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for MSPR.Check FOXO's competition here
MSPR vs MSPRW Comparison April 2026
MSPR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MSPR stands at 427K. In comparison, MSPRW has a market cap of 2.8K. Regarding current trading prices, MSPR is priced at $0.03, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MSPR currently has a P/E ratio of N/A, whereas MSPRW's P/E ratio is N/A. In terms of profitability, MSPR's ROE is +3.93%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, MSPR is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for MSPR.Check MSPRW's competition here